Photo Release -- Noodles & Company Introduces New Limited

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Photo Release -- Noodles & Company Introduces New Limited Time Only Menu Offerings

BROOMFIELD, Colo., Oct. 2, 2013 (GLOBE NEWSWIRE) -- Noodles & Company (Nasdaq: NDLS ) serving classic noodle and pasta dishes from around the world, today announced the launch of three new menu items, including flavors from Latin America, a new global influence to the Noodles & Company menu. The new menu items include the Thai Hot Pot , Spaghetti Alfredo MontAmore® and Pork Adobo Flatbread , which will be available at all restaurants nationwide until March 2014.

A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=21339

Noodle & Company's new fall and winter menu items include:

  • Thai Hot Pot – A 30-ingredient curry broth made with a fresh cabbage blend, sprouts, Fresno peppers and shiitake mushrooms with a sprinkling of rice noodles and pulled chicken and naturally-raised pork. It is finished with a lime wedge and sprig of cilantro, served with a side of toasted Asian flatbread.
     
  • Spaghetti Alfredo MontAmore® – Spaghetti noodles tossed with a decadent four cheese blend, roasted mushrooms and grape tomatoes, spinach and Parmesan chicken. It is topped with a sprinkle of MontAmore® cheese, parsley and fresh cracked pepper. The MontAmore cheese, though inspired by Piave (an Italian cheese), is made with milk that comes directly from independently owned, patron farms all of which are located within 50 miles of the Sartori Cheese headquarters in Wisconsin.
     
  • Pork Adobo Flatbread – Features spicy Latin adobo flavors of toasted cumin and fire-roasted tomatoes, naturally raised pork, cheese and Fresno peppers toasted atop flatbread and finished with fresh lime and cilantro. 

With the addition of the spicy, smoky, Pork Adobo Flatbread, Noodles & Company further develops its concept of Your World Kitchen by utilizing ingredients like red bell peppers, roasted cumin, jalapeños to spice traditional comfort foods. Noodles & Company has more than 340 restaurant locations across the United States and delivers its globally inspired, cooked-to-order menu in a real bowl, delivered to the table with a smile. Its menu consists of more than 25 fresh, customizable dishes that are prepared quickly with quality ingredients. Favorites include the sweet and spicy Japanese Pan Noodles, zesty Pesto Cavatappi and the popular Wisconsin Mac & Cheese.

About Noodles & Company

Noodles & Company is a fast-casual restaurant chain where its globally-inspired dishes come together to create Your World Kitchen .  It is a restaurant where Japanese Pan Noodles rest comfortably next to Penne Rosa and Wisconsin Mac & Cheese, but where world flavors don't end at just noodles.  Inspired by some of the world's most celebrated flavor combinations, Noodle & Company's menu offers appetizers, soups, salads and sandwiches, too. Everything is made fresh to order, just as you like it, using quality ingredients.  Dishes are delivered to the table allowing guests time to sit and relax or grab a quick bite.  With more than 300 locations nationwide, from California to Connecticut, guests can find a location nearest them and take a tour of the global menu by visiting www.noodles.com .

The photo is also available via AP PhotoExpress.

Source: Noodles & Company

Media Inquiries: Jeff Dorman, ICR 203.682.8324

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 35

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 26

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 23

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 32

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Kotak Mahindra Bank's Innovative Tech Strategies

Updated Category News Views 587

Kotak Mahindra Bank's Commitment to Digital Transformation Kotak Mahindra Bank is at the forefront of revolutionizing financial services through its innovative technology strategies. Their latest report dives deep into the bank's extensive tech activities, highlighting how it leverages digital transformation to enhance customer experience and streamline operations....

Continue Reading
Star Group, L.P. Reflects on Fiscal 2024 Performance Updates

Updated Category News Views 349

Star Group's Fiscal 2024 Insights and Performance Analysis As the fiscal year wraps up, Star Group, L.P. (NYSE: SGU), a respected home energy distributor, shares its financial performance that ended on September 30, 2024. Amidst the prevailing challenges in the energy market, the company continues its commitment to delivering quality services while adapting to market...

Continue Reading
Krystal Biotech Launches Clinical Trial for Eye Therapy KB801

Updated Category News Views 148

Krystal Biotech Begins Phase 1/2 Trial of KB801 Krystal Biotech, Inc. (NASDAQ: KRYS) has recently announced exciting developments in its ophthalmology pipeline with the initiation of a Phase 1/2 clinical trial for KB801, aimed at treating neurotrophic keratitis (NK). This 2:1 randomized, double-masked, multicenter, placebo-controlled study, named EMERALD-1, marks a...

Continue Reading
Key Updates on the Annual General Meeting of Ignitis Group

Updated Category News Views 163

Exciting Updates for the Ignitis Group Shareholders The retained earnings figure for AB “Ignitis grup?” has been amended for the upcoming Annual General Meeting. It now stands at EUR 320,319,368.41, following a revision made only to the English version of the document. This adjustment reflects the company’s commitment to transparency and accuracy in their financial...

Continue Reading
Transforming Connectivity: The Future of mmWave Sensors Growth

Updated Category News Views 104

The mmWave sensors market was set on a blistering growth path back in 2023, valued at around USD 0.25 billion. By the time you fast-forward to 2032, projections had it skyrocketing to USD 2.40 billion, boasting a staggering CAGR of 28.59% from 2024 through 2032. You'd think this kind of momentum would have traders buzzing—oh wait, they were, especially as the push for...

Continue Reading